New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

What clinical or logistical factors influence your choice of anti-CD38 antibody in first-line treatment of multiple myeloma?

2
5 Answers

Mednet Member
Medical Oncology · University of Utah Health

I generally use daratumumab, because subcutaneous is more convenient for patients, and we go to once-a-month dosing much quicker with daratumumab compared to isatuximab. Once isatuximab subcutaneous is available, this advantage of daratumumab may be lost, but given comfort and familiarity with darat...

Does receiving IVIG confound the result of SPEP and/or UPEP?

4
2 Answers

Mednet Member
Hematology · John Theurer Cancer Center at Hackensack University Medical Center

IVIG being a product of polyclonal immunoglobulins may ‘produce’ a monoclonal spike if the AUC is falsely calculated by the reader. IFE usually shows polyclonal banding but every now and then a monoclonal band is picked up. Being an IgG molecule with a 21 day halflife; and with the assumption that i...

Would you use bone marrow MRD status to guide stopping daratumumab early at 1 year instead of the recommended 3 years of therapy per the AQUILA trial for high-risk smoldering myeloma?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Chicago

I would venture to say that there is probably a 0% chance that MRD negativity would be achieved with daratumumab alone. The CR rate was 8.8%, but MRD was not assessed, and I would doubt that MRD negativity was achieved in any patient. That said, we can't really extrapolate whether 1 year and stoppin...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What radiation dose do you typically use for relapsed DLBCL following 6 cycles of R-CHOP?

2
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

There are several potential scenarios, all with different answers, so I will illustrate a few.Historically, second-line chemotherapy (e.g., R-ICE) would first be pursued for relapsed DLBCL, and if the disease was still responsive to chemotherapy (CR or PR), then the patient would proceed with high-d...

How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · The Robert Larner, M.D. College of Medicine at The University of Vermont

When using azacitidine for the treatment of MDS, I adjust the dose in case of cytopenia for cycle 2 onwards. If there was no baseline cytopenia (ANC >1.5, PLT >75K) but cytopenia developed with treatment, the subsequent cycle is delayed until counts recover, and the dose is based on the nadir and t...

What is your approach to optimizing pre-operative hemoglobin in patients with sickle cell disease?

2 Answers

Mednet MemberInvited Expert
Hospital Medicine · Johns Hopkins Hospital

This is always a question that has to be hyper-individualized. The research, and therefore the associated professional guidance, is thin. The American Society of Hematology (ASH) 2020 Guidelines for Sickle Cell Disease: Transfusion Support and the NHLBI Expert Panel Report (2014) are the only profes...

For low/intermediate essential thrombocythemia not on cytoreduction, would you temporarily cytoreduce in anticipation of surgery?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Johns Hopkins University

First, I am going to answer this question with a question. What is low/intermediate essential thrombocytosis (ET)? I ask this question because we are living in the 21st century in the midst of the genomic era, and it is far past the time that we should be dwelling on phenotype instead of employing p...

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...

Do you continue daratumumab beyond 24 months in first line treatment of amyloidosis?

3 Answers

Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester

This is an important and common clinical question, and one for which prospective data are currently limited. For background, the ANDROMEDA clinical trial (Kastritis et al., PMID 34192431) demonstrated that the addition of daratumumab to cyclophosphamide, bortezomib, and dexamethasone (CyBorD) signif...

Would you consider upfront, time-limited anti-IL-5 therapy for I-HES or L-HES to avoid steroid side effects?

1 Answers

Mednet MemberInvited Expert
Hematology · Dalhousie University, Canada

There are two parts to this question: Are there better options than steroids for the treatment of iHES and L-HES? The answer is an emphatic yes. These are chronic diseases, and steroids are really not the optimal therapy. IL-5 inhibitors such as mepolizumab and benralizumab are effective in reducing...